320782-17-0

Usage

Uses

Used in Pharmaceutical Research and Development:
5-(Trifluoromethyl)-1H-indole-3-ethanamine is used as a research chemical for the development of new drugs, particularly those targeting the serotonin system. Its affinity for serotonin receptors suggests potential applications in the treatment of neuropsychiatric disorders.
Used in Neuropharmacological Studies:
In the field of neuropharmacology, 5-(Trifluoromethyl)-1H-indole-3-ethanamine is used as a tool compound to study the mechanisms of action and effects of psychoactive substances on the central nervous system. This helps in understanding the role of serotonin in mood, perception, and other cognitive functions.
Used in Drug Discovery for Neuropsychiatric Disorders:
5-(Trifluoromethyl)-1H-indole-3-ethanamine is utilized in drug discovery processes aimed at identifying novel therapeutic agents for the treatment of neuropsychiatric disorders such as depression, anxiety, and schizophrenia. Its interaction with serotonin receptors may offer new avenues for symptom management and treatment.
Used in Chemical Synthesis:
In the chemical synthesis industry, 5-(Trifluoromethyl)-1H-indole-3-ethanamine may be used as a building block or intermediate in the synthesis of more complex molecules with potential pharmaceutical or chemical applications.

Upstream product

• 16686-11-6 2-(3-chloropropyl)-1,3-dioxolane 
• 368-90-1 4-(trifluoromethyl)phenylhydrazine 
• 163444-17-5 2-iodo-4-(trifluoromethyl)aniline 
• 455-14-1 4-trifluoromethylphenylamine 
• 1258504-16-3 2-(2-(triethylsilyl)-5-(trifluoromethyl)-1H-indol-3-yl)ethanol 
• 1258504-17-4 3-(2-bromoethyl)-2-(triethylsilyl)-5-(trifluoromethyl)-1H-indole 
• 1258504-18-5 3-(2-azidoethyl)-2-(triethylsilyl)-5-(trifluoromethyl)-1H-indole 
• 1426062-24-9 3-(2-bromoethyl)-5-(trifluoromethyl)-1H-indole 
• 29882-07-3 4-chlorobutanal dimethyl acetal 
• 2923-56-0 4-(trifluoromethyl)phenylhydrazine hydrochloride 
• 320782-16-9 2-(2-triethylsilanyl-5-trifluoromethyl-1H-indol-3-yl)ethylamine 

Downstream Products

• 78832-75-4 6-trifluoromethyl-1,3,4,9-tetrahydro-1H-β-carboline 

Relevant academic research and scientific papers

fragrant alkane acyl tetrahydro-β-Carboline and its derivatives in the treatment of malignant tumors

The present invention discloses an aromatic alkanoyl tetrahydro-beta-carboline compound represented by a structural formula (I), and related analogs thereof or hydrates or pharmaceutically acceptable salts thereof, and the application of the compound or p

fragrant alkane acyl tetrahydro-β-Carboline and its derivatives in the treatment of metabolic diseases

The present invention discloses an aromatic alkanoyl tetrahydro-beta-carboline compound represented by a structural formula (I), and related analogs thereof or hydrates or pharmaceutically acceptable salts thereof, and the application of the compound or p

ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME

The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity,methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-γ in a subject.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

New synthetic technologies for the construction of heterocycles and tryptamines

New synthetic methods for the construction of novel heterocycles and tryptamines are described. Thus, N-Boc anilines (I) are sequentially converted to heterocycles II ((3-(2-aminophenyl)pyrrolidin-3-ol) derivatives),III (substituted 2-oxo-1,2-dihydrospirobenzo[d][1,3]oxazine-4,3'-pyrrol idines), and VI (2-(4,5-dihydro-1H-pyrrol-3-yl)aniline) derivatives through a route involving t-BuLi induced ortho-metalation/ LaCl3 2LiCl metalexchange, reaction with N-Boc pyrrolidin-3-one (5), and subsequent deca rboxylative fragmentation. Labile intermediates VI are effectively converted to tryptamines Xa and Xb under controlled proticacidconditions.Inadditiontoprovidingexpedientaccesstothe2-oxo- 1,2-dihydrospirobenzo[d][1,3]oxazine-4,3'-pyrrolidines (III), the method is applicable to the synthesis of the corresponding 2-oxo-1,2-dihydrospirobenzo[d] [1,3]oxazine-4,3'-piperidine series of spirocycles (e.g., 42) and their precursors (3-(2-aminophenyl)piperidin-3-ol derivatives, e.g., 43) by using N-Boc-protected piperidin-3-one (40). Applications of the developed synthetic technologies to the synthesis of regioisomeric spirocycles 87 and 90, tryptamines 88 and 91, Corey's aspidophytine tryptamine (97), and efavirenz (1) are also described.

An expedient strategy for the synthesis of tryptamines and other heterocycles

(Chemical Equation Presented) Making many from one: N-Boc-protected anilines are converted into an array of useful N-heterocycles and tryptamines through an expedient, cascade-based synthetic sequence involving ortho metalation and subsequent coupling wit